Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 clinical trials
Its developmentBy ImmVira Pharma and Shanghai Pharmaceuticals, step by step8 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- T3011
- 8
Studies by the year they started
11 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 3
ImmVira Pharma Co. Ltd (6) · Shanghai Pharmaceuticals Holding Co., Ltd (2) · West China Hospital (2) · China Medical University, China (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011.
- Dec 2026A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid TumorsPhase 1/2 · Shanghai Pharmaceuticals Holding Co., Ltd
Studies
Open first, then newest update. How each study uses Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBCRecruitingPhase 2ImmVira Pharma Co. LtdNCT06971614Written as T3011How we know
- A Clinical Study of T3011 in Subjects With Advanced MelanomaRecruitingPhase 1/2Shanghai Pharmaceuticals Holding Co., LtdNCT06214156Written as T3011How we know
- A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Pharmaceuticals Holding Co., LtdNCT06214143Written as T3011 high doseHow we know
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2ImmVira Pharma Co. LtdNCT04370587Written as T3011How we know
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingPhase 1China Medical University, ChinaNCT06283303Written as T3011 hepatic artery infusionHow we know
- A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal CancerRecruitingPhase 1West China HospitalNCT06200376Written as T3011How we know
- A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal CancerRecruitingPhase 1West China HospitalNCT06200363Written as T3011How we know
- Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid TumorsActive, not recruitingPhase 1/2ImmVira Pharma Co. LtdNCT04780217Written as T3011How we know
- T3011 in Combination With Cobimetinib in Patients With Advanced MelanomaSuspendedPhase 2ImmVira Pharma Co. LtdNCT05756556Written as T3011 + CobimetinibHow we know
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownPhase 1/2ImmVira Pharma Co. LtdNCT05602792Written as T3011How we know
- A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.Status unknownPhase 1/2ImmVira Pharma Co. LtdNCT05598268Written as T3011How we know